A potential link between Ad-36 and obesity-related nonalcoholic fatty liver disease (NAFLD) development relies on leptin gene expression and insulin sensitivity reduction, glucose uptake increase, lipogenic and pro-inflammatory pathway activation in adipose tissue, and macrophage chemoattractant protein-1 elevation [63]. The gene discussed is LEP; the disease is metabolic dysfunction-associated steatotic liver disease.